nodes	percent_of_prediction	percent_of_DWPC	metapath
Lubiprostone—CBR1—Doxorubicin—lung cancer	0.573	1	CbGbCtD
Lubiprostone—CLCN2—respiratory system—lung cancer	0.0163	0.191	CbGeAlD
Lubiprostone—CLCN2—epithelium—lung cancer	0.0136	0.16	CbGeAlD
Lubiprostone—CBR1—mammary gland—lung cancer	0.00979	0.115	CbGeAlD
Lubiprostone—CLCN2—lung—lung cancer	0.00864	0.102	CbGeAlD
Lubiprostone—CBR1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—HPGDS—lung cancer	0.00833	0.111	CbGpPWpGaD
Lubiprostone—CBR1—respiratory system—lung cancer	0.00652	0.0767	CbGeAlD
Lubiprostone—CLCN2—lymph node—lung cancer	0.00591	0.0694	CbGeAlD
Lubiprostone—CBR1—bronchus—lung cancer	0.00537	0.0631	CbGeAlD
Lubiprostone—CBR1—trachea—lung cancer	0.00482	0.0566	CbGeAlD
Lubiprostone—CBR1—cardiac atrium—lung cancer	0.00453	0.0532	CbGeAlD
Lubiprostone—CBR1—bone marrow—lung cancer	0.00382	0.0449	CbGeAlD
Lubiprostone—CBR1—lung—lung cancer	0.00346	0.0407	CbGeAlD
Lubiprostone—CBR1—Vincristine—Vinorelbine—lung cancer	0.00335	0.46	CbGdCrCtD
Lubiprostone—Dinoprostone—HPGDS—lung cancer	0.00333	1	CrCbGaD
Lubiprostone—CBR1—Arachidonic acid metabolism—HPGDS—lung cancer	0.00301	0.04	CbGpPWpGaD
Lubiprostone—CBR1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—PTGS2—lung cancer	0.0029	0.0386	CbGpPWpGaD
Lubiprostone—CBR1—Vincristine—Vinblastine—lung cancer	0.00268	0.367	CbGdCrCtD
Lubiprostone—CLCN2—Transmembrane transport of small molecules—SLC34A2—lung cancer	0.00263	0.035	CbGpPWpGaD
Lubiprostone—CBR1—NRF2 pathway—PRDX1—lung cancer	0.00248	0.033	CbGpPWpGaD
Lubiprostone—CBR1—lymph node—lung cancer	0.00237	0.0278	CbGeAlD
Lubiprostone—CBR1—NRF2 pathway—GSTM2—lung cancer	0.00233	0.031	CbGpPWpGaD
Lubiprostone—CLCN2—Transmembrane transport of small molecules—SLC22A18—lung cancer	0.00199	0.0265	CbGpPWpGaD
Lubiprostone—CBR1—NRF2 pathway—GSTA3—lung cancer	0.00188	0.025	CbGpPWpGaD
Lubiprostone—CBR1—NRF2 pathway—KEAP1—lung cancer	0.00177	0.0235	CbGpPWpGaD
Lubiprostone—CBR1—Arachidonic acid metabolism—CYP1A1—lung cancer	0.00176	0.0234	CbGpPWpGaD
Lubiprostone—CBR1—NRF2 pathway—GSTA4—lung cancer	0.00172	0.0229	CbGpPWpGaD
Lubiprostone—CBR1—NRF2 pathway—GSTA2—lung cancer	0.00167	0.0223	CbGpPWpGaD
Lubiprostone—CBR1—NRF2 pathway—GSTA1—lung cancer	0.00162	0.0215	CbGpPWpGaD
Lubiprostone—CBR1—NRF2 pathway—ABCC3—lung cancer	0.0016	0.0212	CbGpPWpGaD
Lubiprostone—CLCN2—Stimuli-sensing channels—RAF1—lung cancer	0.00151	0.0201	CbGpPWpGaD
Lubiprostone—CBR1—NRF2 pathway—UGT1A1—lung cancer	0.0015	0.02	CbGpPWpGaD
Lubiprostone—CBR1—NRF2 pathway—NFE2L2—lung cancer	0.00142	0.0189	CbGpPWpGaD
Lubiprostone—CBR1—NRF2 pathway—TGFA—lung cancer	0.00136	0.0181	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—COL4A3BP—lung cancer	0.0013	0.0172	CbGpPWpGaD
Lubiprostone—CBR1—Azacitidine—Gemcitabine—lung cancer	0.00126	0.173	CbGdCrCtD
Lubiprostone—CBR1—NRF2 pathway—GCLC—lung cancer	0.00122	0.0163	CbGpPWpGaD
Lubiprostone—CBR1—NRF2 pathway—CYP2A6—lung cancer	0.00122	0.0163	CbGpPWpGaD
Lubiprostone—CLCN2—Transmembrane transport of small molecules—ABCC3—lung cancer	0.00119	0.0159	CbGpPWpGaD
Lubiprostone—CLCN2—Transmembrane transport of small molecules—GNG11—lung cancer	0.00108	0.0144	CbGpPWpGaD
Lubiprostone—CBR1—Arachidonic acid metabolism—PTGS2—lung cancer	0.00105	0.0139	CbGpPWpGaD
Lubiprostone—CBR1—NRF2 pathway—NQO1—lung cancer	0.00103	0.0137	CbGpPWpGaD
Lubiprostone—CLCN2—Ion channel transport—RAF1—lung cancer	0.000988	0.0131	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—PLBD1—lung cancer	0.000982	0.0131	CbGpPWpGaD
Lubiprostone—CLCN2—Transmembrane transport of small molecules—ADCY1—lung cancer	0.000974	0.013	CbGpPWpGaD
Lubiprostone—CLCN2—Transmembrane transport of small molecules—ABCG2—lung cancer	0.000974	0.013	CbGpPWpGaD
Lubiprostone—CLCN2—Transmembrane transport of small molecules—TF—lung cancer	0.000906	0.012	CbGpPWpGaD
Lubiprostone—CBR1—NRF2 pathway—GSTP1—lung cancer	0.000859	0.0114	CbGpPWpGaD
Lubiprostone—CBR1—NRF2 pathway—GSTM1—lung cancer	0.000789	0.0105	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—MTMR3—lung cancer	0.000764	0.0102	CbGpPWpGaD
Lubiprostone—CLCN2—Transmembrane transport of small molecules—AVP—lung cancer	0.000628	0.00835	CbGpPWpGaD
Lubiprostone—CLCN2—Transmembrane transport of small molecules—ABCB1—lung cancer	0.000608	0.00808	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—AZIN2—lung cancer	0.000577	0.00767	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—COL4A3BP—lung cancer	0.000577	0.00767	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—ABCC3—lung cancer	0.000538	0.00716	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—AKR1C1—lung cancer	0.000521	0.00693	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—ATP5H—lung cancer	0.000491	0.00653	CbGpPWpGaD
Lubiprostone—CLCN2—Transmembrane transport of small molecules—APOA1—lung cancer	0.00048	0.00638	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—NCOA3—lung cancer	0.000451	0.006	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—PLBD1—lung cancer	0.000437	0.00582	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—HPGDS—lung cancer	0.00043	0.00572	CbGpPWpGaD
Lubiprostone—CLCN2—Transmembrane transport of small molecules—CREBBP—lung cancer	0.000406	0.0054	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—HSD17B10—lung cancer	0.0004	0.00532	CbGpPWpGaD
Lubiprostone—CLCN2—Transmembrane transport of small molecules—ALB—lung cancer	0.00038	0.00506	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—CKB—lung cancer	0.000372	0.00495	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—GSTM2—lung cancer	0.00035	0.00465	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—CNDP2—lung cancer	0.00035	0.00465	CbGpPWpGaD
Lubiprostone—CLCN2—Transmembrane transport of small molecules—RAF1—lung cancer	0.000344	0.00457	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—MTMR3—lung cancer	0.00034	0.00452	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—PGAM1—lung cancer	0.000331	0.00441	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—CYP2A7—lung cancer	0.000316	0.0042	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—SDC4—lung cancer	0.000309	0.00411	CbGpPWpGaD
Lubiprostone—Headache—Erlotinib—lung cancer	0.000286	0.00112	CcSEcCtD
Lubiprostone—Loss of consciousness—Paclitaxel—lung cancer	0.000286	0.00112	CcSEcCtD
Lubiprostone—Hyperhidrosis—Cisplatin—lung cancer	0.000285	0.00111	CcSEcCtD
Lubiprostone—Mediastinal disorder—Docetaxel—lung cancer	0.000285	0.00111	CcSEcCtD
Lubiprostone—Cough—Paclitaxel—lung cancer	0.000284	0.00111	CcSEcCtD
Lubiprostone—Asthenia—Vinorelbine—lung cancer	0.000283	0.0011	CcSEcCtD
Lubiprostone—Decreased appetite—Irinotecan—lung cancer	0.000283	0.0011	CcSEcCtD
Lubiprostone—Dyspnoea—Gemcitabine—lung cancer	0.000282	0.0011	CcSEcCtD
Lubiprostone—Chest pain—Etoposide—lung cancer	0.000282	0.0011	CcSEcCtD
Lubiprostone—CBR1—Metabolism—RRM1—lung cancer	0.000282	0.00375	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—GSTA3—lung cancer	0.000282	0.00375	CbGpPWpGaD
Lubiprostone—Nausea—Vinblastine—lung cancer	0.000282	0.0011	CcSEcCtD
Lubiprostone—Anorexia—Cisplatin—lung cancer	0.000281	0.0011	CcSEcCtD
Lubiprostone—Gastrointestinal disorder—Irinotecan—lung cancer	0.000281	0.0011	CcSEcCtD
Lubiprostone—Fatigue—Irinotecan—lung cancer	0.00028	0.00109	CcSEcCtD
Lubiprostone—Unspecified disorder of skin and subcutaneous tissue—Etoposide—lung cancer	0.00028	0.00109	CcSEcCtD
Lubiprostone—Discomfort—Etoposide—lung cancer	0.000279	0.00109	CcSEcCtD
Lubiprostone—Pain—Irinotecan—lung cancer	0.000278	0.00109	CcSEcCtD
Lubiprostone—Constipation—Irinotecan—lung cancer	0.000278	0.00109	CcSEcCtD
Lubiprostone—Mental disorder—Docetaxel—lung cancer	0.000277	0.00108	CcSEcCtD
Lubiprostone—Myalgia—Paclitaxel—lung cancer	0.000277	0.00108	CcSEcCtD
Lubiprostone—Chest pain—Paclitaxel—lung cancer	0.000277	0.00108	CcSEcCtD
Lubiprostone—Anxiety—Paclitaxel—lung cancer	0.000276	0.00108	CcSEcCtD
Lubiprostone—Malnutrition—Docetaxel—lung cancer	0.000275	0.00108	CcSEcCtD
Lubiprostone—Erythema—Docetaxel—lung cancer	0.000275	0.00108	CcSEcCtD
Lubiprostone—Decreased appetite—Gemcitabine—lung cancer	0.000275	0.00108	CcSEcCtD
Lubiprostone—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—lung cancer	0.000275	0.00107	CcSEcCtD
Lubiprostone—Nausea—Topotecan—lung cancer	0.000274	0.00107	CcSEcCtD
Lubiprostone—Gastrointestinal disorder—Gemcitabine—lung cancer	0.000273	0.00107	CcSEcCtD
Lubiprostone—Discomfort—Paclitaxel—lung cancer	0.000273	0.00107	CcSEcCtD
Lubiprostone—Abdominal discomfort—Methotrexate—lung cancer	0.000273	0.00107	CcSEcCtD
Lubiprostone—Fatigue—Gemcitabine—lung cancer	0.000273	0.00107	CcSEcCtD
Lubiprostone—Constipation—Gemcitabine—lung cancer	0.000271	0.00106	CcSEcCtD
Lubiprostone—Pain—Gemcitabine—lung cancer	0.000271	0.00106	CcSEcCtD
Lubiprostone—Nausea—Erlotinib—lung cancer	0.000271	0.00106	CcSEcCtD
Lubiprostone—Dry mouth—Paclitaxel—lung cancer	0.000271	0.00106	CcSEcCtD
Lubiprostone—Diarrhoea—Vinorelbine—lung cancer	0.00027	0.00105	CcSEcCtD
Lubiprostone—Dysgeusia—Docetaxel—lung cancer	0.00027	0.00105	CcSEcCtD
Lubiprostone—Musculoskeletal discomfort—Cisplatin—lung cancer	0.000269	0.00105	CcSEcCtD
Lubiprostone—Feeling abnormal—Irinotecan—lung cancer	0.000268	0.00105	CcSEcCtD
Lubiprostone—Gastrointestinal pain—Irinotecan—lung cancer	0.000266	0.00104	CcSEcCtD
Lubiprostone—Oedema—Paclitaxel—lung cancer	0.000265	0.00104	CcSEcCtD
Lubiprostone—CBR1—Metabolism—B4GALT5—lung cancer	0.000265	0.00352	CbGpPWpGaD
Lubiprostone—Muscle spasms—Docetaxel—lung cancer	0.000265	0.00103	CcSEcCtD
Lubiprostone—Tachycardia—Etoposide—lung cancer	0.000264	0.00103	CcSEcCtD
Lubiprostone—Dyspnoea—Cisplatin—lung cancer	0.000263	0.00103	CcSEcCtD
Lubiprostone—Skin disorder—Etoposide—lung cancer	0.000263	0.00103	CcSEcCtD
Lubiprostone—Hyperhidrosis—Etoposide—lung cancer	0.000261	0.00102	CcSEcCtD
Lubiprostone—Feeling abnormal—Gemcitabine—lung cancer	0.000261	0.00102	CcSEcCtD
Lubiprostone—Shock—Paclitaxel—lung cancer	0.000261	0.00102	CcSEcCtD
Lubiprostone—Dizziness—Vinorelbine—lung cancer	0.000261	0.00102	CcSEcCtD
Lubiprostone—Nervous system disorder—Paclitaxel—lung cancer	0.00026	0.00102	CcSEcCtD
Lubiprostone—Tachycardia—Paclitaxel—lung cancer	0.000259	0.00101	CcSEcCtD
Lubiprostone—Anorexia—Etoposide—lung cancer	0.000258	0.00101	CcSEcCtD
Lubiprostone—CBR1—Metabolism—GSTA4—lung cancer	0.000258	0.00343	CbGpPWpGaD
Lubiprostone—Skin disorder—Paclitaxel—lung cancer	0.000258	0.00101	CcSEcCtD
Lubiprostone—Abdominal pain—Irinotecan—lung cancer	0.000257	0.001	CcSEcCtD
Lubiprostone—Aspartate aminotransferase increased—Doxorubicin—lung cancer	0.000257	0.001	CcSEcCtD
Lubiprostone—Decreased appetite—Cisplatin—lung cancer	0.000257	0.001	CcSEcCtD
Lubiprostone—Hyperhidrosis—Paclitaxel—lung cancer	0.000256	0.001	CcSEcCtD
Lubiprostone—Gastrointestinal disorder—Cisplatin—lung cancer	0.000255	0.000995	CcSEcCtD
Lubiprostone—Anorexia—Paclitaxel—lung cancer	0.000253	0.000987	CcSEcCtD
Lubiprostone—Gastritis—Doxorubicin—lung cancer	0.000253	0.000986	CcSEcCtD
Lubiprostone—Pain—Cisplatin—lung cancer	0.000252	0.000986	CcSEcCtD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—CYP1A1—lung cancer	0.000252	0.00335	CbGpPWpGaD
Lubiprostone—Alanine aminotransferase increased—Doxorubicin—lung cancer	0.000252	0.000983	CcSEcCtD
Lubiprostone—CBR1—Metabolism—GSTA2—lung cancer	0.000251	0.00334	CbGpPWpGaD
Lubiprostone—Vomiting—Vinorelbine—lung cancer	0.000251	0.000979	CcSEcCtD
Lubiprostone—Rash—Vinorelbine—lung cancer	0.000249	0.000971	CcSEcCtD
Lubiprostone—Dermatitis—Vinorelbine—lung cancer	0.000248	0.00097	CcSEcCtD
Lubiprostone—Abdominal distension—Doxorubicin—lung cancer	0.000248	0.00097	CcSEcCtD
Lubiprostone—Headache—Vinorelbine—lung cancer	0.000247	0.000965	CcSEcCtD
Lubiprostone—Syncope—Docetaxel—lung cancer	0.000247	0.000965	CcSEcCtD
Lubiprostone—Influenza—Doxorubicin—lung cancer	0.000247	0.000963	CcSEcCtD
Lubiprostone—Palpitations—Docetaxel—lung cancer	0.000243	0.000951	CcSEcCtD
Lubiprostone—Feeling abnormal—Cisplatin—lung cancer	0.000243	0.00095	CcSEcCtD
Lubiprostone—CBR1—Metabolism—GSTA1—lung cancer	0.000242	0.00322	CbGpPWpGaD
Lubiprostone—Loss of consciousness—Docetaxel—lung cancer	0.000242	0.000945	CcSEcCtD
Lubiprostone—Musculoskeletal discomfort—Paclitaxel—lung cancer	0.000242	0.000944	CcSEcCtD
Lubiprostone—Dyspnoea—Etoposide—lung cancer	0.000241	0.000942	CcSEcCtD
Lubiprostone—Cough—Docetaxel—lung cancer	0.00024	0.000939	CcSEcCtD
Lubiprostone—CBR1—Metabolism—ABCC3—lung cancer	0.00024	0.00319	CbGpPWpGaD
Lubiprostone—Hypersensitivity—Irinotecan—lung cancer	0.00024	0.000936	CcSEcCtD
Lubiprostone—Dyspnoea—Paclitaxel—lung cancer	0.000236	0.000923	CcSEcCtD
Lubiprostone—Decreased appetite—Etoposide—lung cancer	0.000235	0.000918	CcSEcCtD
Lubiprostone—Myalgia—Docetaxel—lung cancer	0.000234	0.000916	CcSEcCtD
Lubiprostone—Chest pain—Docetaxel—lung cancer	0.000234	0.000916	CcSEcCtD
Lubiprostone—Nausea—Vinorelbine—lung cancer	0.000234	0.000915	CcSEcCtD
Lubiprostone—Gastrointestinal disorder—Etoposide—lung cancer	0.000234	0.000912	CcSEcCtD
Lubiprostone—Dyspepsia—Paclitaxel—lung cancer	0.000233	0.000912	CcSEcCtD
Lubiprostone—Asthenia—Irinotecan—lung cancer	0.000233	0.000911	CcSEcCtD
Lubiprostone—Fatigue—Etoposide—lung cancer	0.000233	0.000911	CcSEcCtD
Lubiprostone—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—lung cancer	0.000233	0.000909	CcSEcCtD
Lubiprostone—CBR1—Metabolism—AKR1C1—lung cancer	0.000232	0.00309	CbGpPWpGaD
Lubiprostone—Pain—Etoposide—lung cancer	0.000231	0.000903	CcSEcCtD
Lubiprostone—Constipation—Etoposide—lung cancer	0.000231	0.000903	CcSEcCtD
Lubiprostone—Decreased appetite—Paclitaxel—lung cancer	0.000231	0.0009	CcSEcCtD
Lubiprostone—Dry mouth—Docetaxel—lung cancer	0.000229	0.000896	CcSEcCtD
Lubiprostone—Gastrointestinal disorder—Paclitaxel—lung cancer	0.000229	0.000894	CcSEcCtD
Lubiprostone—Fatigue—Paclitaxel—lung cancer	0.000229	0.000893	CcSEcCtD
Lubiprostone—Pollakiuria—Doxorubicin—lung cancer	0.000228	0.00089	CcSEcCtD
Lubiprostone—Asthenia—Gemcitabine—lung cancer	0.000227	0.000888	CcSEcCtD
Lubiprostone—Constipation—Paclitaxel—lung cancer	0.000227	0.000886	CcSEcCtD
Lubiprostone—Pain—Paclitaxel—lung cancer	0.000227	0.000886	CcSEcCtD
Lubiprostone—CBR1—Metabolism—UGT1A1—lung cancer	0.000225	0.003	CbGpPWpGaD
Lubiprostone—Oedema—Docetaxel—lung cancer	0.000225	0.000878	CcSEcCtD
Lubiprostone—Weight increased—Doxorubicin—lung cancer	0.000225	0.000877	CcSEcCtD
Lubiprostone—Feeling abnormal—Etoposide—lung cancer	0.000223	0.00087	CcSEcCtD
Lubiprostone—Diarrhoea—Irinotecan—lung cancer	0.000222	0.000869	CcSEcCtD
Lubiprostone—Gastrointestinal pain—Etoposide—lung cancer	0.000221	0.000864	CcSEcCtD
Lubiprostone—Shock—Docetaxel—lung cancer	0.000221	0.000864	CcSEcCtD
Lubiprostone—Nervous system disorder—Docetaxel—lung cancer	0.00022	0.000861	CcSEcCtD
Lubiprostone—Tachycardia—Docetaxel—lung cancer	0.000219	0.000857	CcSEcCtD
Lubiprostone—Feeling abnormal—Paclitaxel—lung cancer	0.000219	0.000853	CcSEcCtD
Lubiprostone—Skin disorder—Docetaxel—lung cancer	0.000218	0.000853	CcSEcCtD
Lubiprostone—Hypersensitivity—Cisplatin—lung cancer	0.000218	0.000849	CcSEcCtD
Lubiprostone—CBR1—Metabolism—GNG11—lung cancer	0.000217	0.00289	CbGpPWpGaD
Lubiprostone—Gastrointestinal pain—Paclitaxel—lung cancer	0.000217	0.000847	CcSEcCtD
Lubiprostone—Diarrhoea—Gemcitabine—lung cancer	0.000217	0.000846	CcSEcCtD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—APOA1—lung cancer	0.000216	0.00287	CbGpPWpGaD
Lubiprostone—Dizziness—Irinotecan—lung cancer	0.000215	0.00084	CcSEcCtD
Lubiprostone—Anorexia—Docetaxel—lung cancer	0.000214	0.000837	CcSEcCtD
Lubiprostone—Abdominal pain—Etoposide—lung cancer	0.000214	0.000835	CcSEcCtD
Lubiprostone—Urinary tract infection—Doxorubicin—lung cancer	0.000214	0.000835	CcSEcCtD
Lubiprostone—Asthenia—Cisplatin—lung cancer	0.000212	0.000827	CcSEcCtD
Lubiprostone—Abdominal pain—Paclitaxel—lung cancer	0.00021	0.000819	CcSEcCtD
Lubiprostone—CBR1—Metabolism—ALDOA—lung cancer	0.000207	0.00275	CbGpPWpGaD
Lubiprostone—Vomiting—Irinotecan—lung cancer	0.000207	0.000807	CcSEcCtD
Lubiprostone—Mediastinal disorder—Methotrexate—lung cancer	0.000206	0.000803	CcSEcCtD
Lubiprostone—Rash—Irinotecan—lung cancer	0.000205	0.000801	CcSEcCtD
Lubiprostone—Dermatitis—Irinotecan—lung cancer	0.000205	0.0008	CcSEcCtD
Lubiprostone—Musculoskeletal discomfort—Docetaxel—lung cancer	0.000205	0.0008	CcSEcCtD
Lubiprostone—Headache—Irinotecan—lung cancer	0.000204	0.000796	CcSEcCtD
Lubiprostone—Diarrhoea—Cisplatin—lung cancer	0.000202	0.000789	CcSEcCtD
Lubiprostone—Vomiting—Gemcitabine—lung cancer	0.000201	0.000786	CcSEcCtD
Lubiprostone—CBR1—Metabolism—NCOA3—lung cancer	0.000201	0.00267	CbGpPWpGaD
Lubiprostone—Dyspnoea—Docetaxel—lung cancer	0.0002	0.000783	CcSEcCtD
Lubiprostone—Mental disorder—Methotrexate—lung cancer	0.0002	0.00078	CcSEcCtD
Lubiprostone—Rash—Gemcitabine—lung cancer	0.0002	0.00078	CcSEcCtD
Lubiprostone—Dermatitis—Gemcitabine—lung cancer	0.0002	0.000779	CcSEcCtD
Lubiprostone—Hypersensitivity—Etoposide—lung cancer	0.000199	0.000778	CcSEcCtD
Lubiprostone—Erythema—Methotrexate—lung cancer	0.000199	0.000775	CcSEcCtD
Lubiprostone—Malnutrition—Methotrexate—lung cancer	0.000199	0.000775	CcSEcCtD
Lubiprostone—Headache—Gemcitabine—lung cancer	0.000198	0.000775	CcSEcCtD
Lubiprostone—Dyspepsia—Docetaxel—lung cancer	0.000198	0.000773	CcSEcCtD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—PIK3CG—lung cancer	0.000197	0.00262	CbGpPWpGaD
Lubiprostone—Decreased appetite—Docetaxel—lung cancer	0.000195	0.000763	CcSEcCtD
Lubiprostone—Hypersensitivity—Paclitaxel—lung cancer	0.000195	0.000763	CcSEcCtD
Lubiprostone—CBR1—Metabolism—ADCY1—lung cancer	0.000195	0.0026	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—ABCG2—lung cancer	0.000195	0.0026	CbGpPWpGaD
Lubiprostone—Oedema peripheral—Doxorubicin—lung cancer	0.000195	0.00076	CcSEcCtD
Lubiprostone—Dysgeusia—Methotrexate—lung cancer	0.000194	0.000759	CcSEcCtD
Lubiprostone—Gastrointestinal disorder—Docetaxel—lung cancer	0.000194	0.000758	CcSEcCtD
Lubiprostone—Asthenia—Etoposide—lung cancer	0.000194	0.000758	CcSEcCtD
Lubiprostone—Connective tissue disorder—Doxorubicin—lung cancer	0.000194	0.000758	CcSEcCtD
Lubiprostone—Fatigue—Docetaxel—lung cancer	0.000194	0.000757	CcSEcCtD
Lubiprostone—Nausea—Irinotecan—lung cancer	0.000193	0.000754	CcSEcCtD
Lubiprostone—Constipation—Docetaxel—lung cancer	0.000192	0.000751	CcSEcCtD
Lubiprostone—Pain—Docetaxel—lung cancer	0.000192	0.000751	CcSEcCtD
Lubiprostone—CBR1—Metabolism—HPGDS—lung cancer	0.000192	0.00255	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—ENO2—lung cancer	0.000192	0.00255	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—PPP2R1B—lung cancer	0.00019	0.00253	CbGpPWpGaD
Lubiprostone—Asthenia—Paclitaxel—lung cancer	0.00019	0.000743	CcSEcCtD
Lubiprostone—Nausea—Gemcitabine—lung cancer	0.000188	0.000735	CcSEcCtD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—POMC—lung cancer	0.000188	0.0025	CbGpPWpGaD
Lubiprostone—Vomiting—Cisplatin—lung cancer	0.000188	0.000733	CcSEcCtD
Lubiprostone—Rash—Cisplatin—lung cancer	0.000186	0.000727	CcSEcCtD
Lubiprostone—Dermatitis—Cisplatin—lung cancer	0.000186	0.000726	CcSEcCtD
Lubiprostone—CBR1—Metabolism—GSTT1—lung cancer	0.000186	0.00247	CbGpPWpGaD
Lubiprostone—Feeling abnormal—Docetaxel—lung cancer	0.000185	0.000723	CcSEcCtD
Lubiprostone—Diarrhoea—Etoposide—lung cancer	0.000185	0.000723	CcSEcCtD
Lubiprostone—Ill-defined disorder—Methotrexate—lung cancer	0.000184	0.000719	CcSEcCtD
Lubiprostone—Gastrointestinal pain—Docetaxel—lung cancer	0.000184	0.000718	CcSEcCtD
Lubiprostone—CBR1—Metabolism—CYP2A6—lung cancer	0.000184	0.00244	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—GCLC—lung cancer	0.000184	0.00244	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—CREBBP—lung cancer	0.000183	0.00243	CbGpPWpGaD
Lubiprostone—Diarrhoea—Paclitaxel—lung cancer	0.000181	0.000709	CcSEcCtD
Lubiprostone—Malaise—Methotrexate—lung cancer	0.000179	0.000699	CcSEcCtD
Lubiprostone—Dizziness—Etoposide—lung cancer	0.000179	0.000698	CcSEcCtD
Lubiprostone—Mediastinal disorder—Doxorubicin—lung cancer	0.000178	0.000695	CcSEcCtD
Lubiprostone—Abdominal pain—Docetaxel—lung cancer	0.000178	0.000694	CcSEcCtD
Lubiprostone—Dizziness—Paclitaxel—lung cancer	0.000175	0.000685	CcSEcCtD
Lubiprostone—Nausea—Cisplatin—lung cancer	0.000175	0.000685	CcSEcCtD
Lubiprostone—CBR1—Metabolism—ENO1—lung cancer	0.000174	0.00232	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—PIK3CD—lung cancer	0.000173	0.00231	CbGpPWpGaD
Lubiprostone—Cough—Methotrexate—lung cancer	0.000173	0.000676	CcSEcCtD
Lubiprostone—Mental disorder—Doxorubicin—lung cancer	0.000173	0.000676	CcSEcCtD
Lubiprostone—Vomiting—Etoposide—lung cancer	0.000172	0.000672	CcSEcCtD
Lubiprostone—Malnutrition—Doxorubicin—lung cancer	0.000172	0.000671	CcSEcCtD
Lubiprostone—Erythema—Doxorubicin—lung cancer	0.000172	0.000671	CcSEcCtD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—ALB—lung cancer	0.000171	0.00228	CbGpPWpGaD
Lubiprostone—Rash—Etoposide—lung cancer	0.000171	0.000666	CcSEcCtD
Lubiprostone—Dermatitis—Etoposide—lung cancer	0.00017	0.000665	CcSEcCtD
Lubiprostone—Headache—Etoposide—lung cancer	0.000169	0.000662	CcSEcCtD
Lubiprostone—Flatulence—Doxorubicin—lung cancer	0.000169	0.000661	CcSEcCtD
Lubiprostone—Chest pain—Methotrexate—lung cancer	0.000169	0.00066	CcSEcCtD
Lubiprostone—Myalgia—Methotrexate—lung cancer	0.000169	0.00066	CcSEcCtD
Lubiprostone—Vomiting—Paclitaxel—lung cancer	0.000169	0.000658	CcSEcCtD
Lubiprostone—Dysgeusia—Doxorubicin—lung cancer	0.000168	0.000657	CcSEcCtD
Lubiprostone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	0.000168	0.000655	CcSEcCtD
Lubiprostone—Rash—Paclitaxel—lung cancer	0.000167	0.000653	CcSEcCtD
Lubiprostone—Dermatitis—Paclitaxel—lung cancer	0.000167	0.000652	CcSEcCtD
Lubiprostone—Discomfort—Methotrexate—lung cancer	0.000167	0.000652	CcSEcCtD
Lubiprostone—Headache—Paclitaxel—lung cancer	0.000166	0.000649	CcSEcCtD
Lubiprostone—Hypersensitivity—Docetaxel—lung cancer	0.000166	0.000647	CcSEcCtD
Lubiprostone—Muscle spasms—Doxorubicin—lung cancer	0.000165	0.000645	CcSEcCtD
Lubiprostone—Asthenia—Docetaxel—lung cancer	0.000161	0.00063	CcSEcCtD
Lubiprostone—Nausea—Etoposide—lung cancer	0.000161	0.000627	CcSEcCtD
Lubiprostone—Ill-defined disorder—Doxorubicin—lung cancer	0.000159	0.000623	CcSEcCtD
Lubiprostone—Nervous system disorder—Methotrexate—lung cancer	0.000159	0.00062	CcSEcCtD
Lubiprostone—Nausea—Paclitaxel—lung cancer	0.000158	0.000615	CcSEcCtD
Lubiprostone—Skin disorder—Methotrexate—lung cancer	0.000157	0.000615	CcSEcCtD
Lubiprostone—Hyperhidrosis—Methotrexate—lung cancer	0.000157	0.000612	CcSEcCtD
Lubiprostone—CBR1—Metabolism—CYP2E1—lung cancer	0.000156	0.00208	CbGpPWpGaD
Lubiprostone—Malaise—Doxorubicin—lung cancer	0.000155	0.000605	CcSEcCtD
Lubiprostone—CBR1—Metabolism—NQO1—lung cancer	0.000154	0.00205	CbGpPWpGaD
Lubiprostone—Anorexia—Methotrexate—lung cancer	0.000154	0.000603	CcSEcCtD
Lubiprostone—Syncope—Doxorubicin—lung cancer	0.000154	0.000602	CcSEcCtD
Lubiprostone—Diarrhoea—Docetaxel—lung cancer	0.000154	0.000601	CcSEcCtD
Lubiprostone—Palpitations—Doxorubicin—lung cancer	0.000152	0.000593	CcSEcCtD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—PIK3CB—lung cancer	0.000151	0.00201	CbGpPWpGaD
Lubiprostone—Loss of consciousness—Doxorubicin—lung cancer	0.000151	0.00059	CcSEcCtD
Lubiprostone—Cough—Doxorubicin—lung cancer	0.00015	0.000586	CcSEcCtD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—PTGS2—lung cancer	0.00015	0.00199	CbGpPWpGaD
Lubiprostone—Dizziness—Docetaxel—lung cancer	0.000149	0.00058	CcSEcCtD
Lubiprostone—Musculoskeletal discomfort—Methotrexate—lung cancer	0.000148	0.000576	CcSEcCtD
Lubiprostone—Chest pain—Doxorubicin—lung cancer	0.000146	0.000571	CcSEcCtD
Lubiprostone—Myalgia—Doxorubicin—lung cancer	0.000146	0.000571	CcSEcCtD
Lubiprostone—Anxiety—Doxorubicin—lung cancer	0.000146	0.00057	CcSEcCtD
Lubiprostone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	0.000145	0.000568	CcSEcCtD
Lubiprostone—Discomfort—Doxorubicin—lung cancer	0.000145	0.000565	CcSEcCtD
Lubiprostone—Dyspnoea—Methotrexate—lung cancer	0.000144	0.000564	CcSEcCtD
Lubiprostone—Dry mouth—Doxorubicin—lung cancer	0.000143	0.000559	CcSEcCtD
Lubiprostone—Vomiting—Docetaxel—lung cancer	0.000143	0.000558	CcSEcCtD
Lubiprostone—Dyspepsia—Methotrexate—lung cancer	0.000143	0.000557	CcSEcCtD
Lubiprostone—Rash—Docetaxel—lung cancer	0.000142	0.000553	CcSEcCtD
Lubiprostone—Dermatitis—Docetaxel—lung cancer	0.000142	0.000553	CcSEcCtD
Lubiprostone—Decreased appetite—Methotrexate—lung cancer	0.000141	0.00055	CcSEcCtD
Lubiprostone—Headache—Docetaxel—lung cancer	0.000141	0.00055	CcSEcCtD
Lubiprostone—Oedema—Doxorubicin—lung cancer	0.00014	0.000548	CcSEcCtD
Lubiprostone—Gastrointestinal disorder—Methotrexate—lung cancer	0.00014	0.000546	CcSEcCtD
Lubiprostone—Fatigue—Methotrexate—lung cancer	0.00014	0.000545	CcSEcCtD
Lubiprostone—CBR1—Metabolism—STK11—lung cancer	0.000139	0.00185	CbGpPWpGaD
Lubiprostone—Pain—Methotrexate—lung cancer	0.000139	0.000541	CcSEcCtD
Lubiprostone—Shock—Doxorubicin—lung cancer	0.000138	0.000539	CcSEcCtD
Lubiprostone—Nervous system disorder—Doxorubicin—lung cancer	0.000138	0.000537	CcSEcCtD
Lubiprostone—Tachycardia—Doxorubicin—lung cancer	0.000137	0.000535	CcSEcCtD
Lubiprostone—Skin disorder—Doxorubicin—lung cancer	0.000136	0.000532	CcSEcCtD
Lubiprostone—Hyperhidrosis—Doxorubicin—lung cancer	0.000136	0.00053	CcSEcCtD
Lubiprostone—Anorexia—Doxorubicin—lung cancer	0.000134	0.000522	CcSEcCtD
Lubiprostone—Nausea—Docetaxel—lung cancer	0.000134	0.000521	CcSEcCtD
Lubiprostone—Feeling abnormal—Methotrexate—lung cancer	0.000134	0.000521	CcSEcCtD
Lubiprostone—Gastrointestinal pain—Methotrexate—lung cancer	0.000132	0.000517	CcSEcCtD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—PTEN—lung cancer	0.000131	0.00174	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—GSTP1—lung cancer	0.000129	0.00171	CbGpPWpGaD
Lubiprostone—Abdominal pain—Methotrexate—lung cancer	0.000128	0.0005	CcSEcCtD
Lubiprostone—Musculoskeletal discomfort—Doxorubicin—lung cancer	0.000128	0.000499	CcSEcCtD
Lubiprostone—CBR1—Metabolism—CAT—lung cancer	0.000125	0.00167	CbGpPWpGaD
Lubiprostone—Dyspnoea—Doxorubicin—lung cancer	0.000125	0.000488	CcSEcCtD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—EP300—lung cancer	0.000125	0.00166	CbGpPWpGaD
Lubiprostone—Dyspepsia—Doxorubicin—lung cancer	0.000123	0.000482	CcSEcCtD
Lubiprostone—Decreased appetite—Doxorubicin—lung cancer	0.000122	0.000476	CcSEcCtD
Lubiprostone—CBR1—Metabolism—ABCB1—lung cancer	0.000122	0.00162	CbGpPWpGaD
Lubiprostone—Gastrointestinal disorder—Doxorubicin—lung cancer	0.000121	0.000473	CcSEcCtD
Lubiprostone—Fatigue—Doxorubicin—lung cancer	0.000121	0.000472	CcSEcCtD
Lubiprostone—Pain—Doxorubicin—lung cancer	0.00012	0.000468	CcSEcCtD
Lubiprostone—Constipation—Doxorubicin—lung cancer	0.00012	0.000468	CcSEcCtD
Lubiprostone—CBR1—Metabolism—TYMS—lung cancer	0.00012	0.00159	CbGpPWpGaD
Lubiprostone—Hypersensitivity—Methotrexate—lung cancer	0.000119	0.000466	CcSEcCtD
Lubiprostone—CBR1—Metabolism—GSTM1—lung cancer	0.000118	0.00157	CbGpPWpGaD
Lubiprostone—Asthenia—Methotrexate—lung cancer	0.000116	0.000454	CcSEcCtD
Lubiprostone—Feeling abnormal—Doxorubicin—lung cancer	0.000116	0.000451	CcSEcCtD
Lubiprostone—Gastrointestinal pain—Doxorubicin—lung cancer	0.000115	0.000448	CcSEcCtD
Lubiprostone—CBR1—Metabolism—CYP1A1—lung cancer	0.000112	0.00149	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—ERCC2—lung cancer	0.000111	0.00148	CbGpPWpGaD
Lubiprostone—Abdominal pain—Doxorubicin—lung cancer	0.000111	0.000433	CcSEcCtD
Lubiprostone—Diarrhoea—Methotrexate—lung cancer	0.000111	0.000433	CcSEcCtD
Lubiprostone—Dizziness—Methotrexate—lung cancer	0.000107	0.000418	CcSEcCtD
Lubiprostone—Hypersensitivity—Doxorubicin—lung cancer	0.000103	0.000404	CcSEcCtD
Lubiprostone—Vomiting—Methotrexate—lung cancer	0.000103	0.000402	CcSEcCtD
Lubiprostone—Rash—Methotrexate—lung cancer	0.000102	0.000399	CcSEcCtD
Lubiprostone—Dermatitis—Methotrexate—lung cancer	0.000102	0.000399	CcSEcCtD
Lubiprostone—Headache—Methotrexate—lung cancer	0.000101	0.000396	CcSEcCtD
Lubiprostone—Asthenia—Doxorubicin—lung cancer	0.000101	0.000393	CcSEcCtD
Lubiprostone—CBR1—Metabolism—APOA1—lung cancer	9.63e-05	0.00128	CbGpPWpGaD
Lubiprostone—Nausea—Methotrexate—lung cancer	9.62e-05	0.000376	CcSEcCtD
Lubiprostone—Diarrhoea—Doxorubicin—lung cancer	9.6e-05	0.000375	CcSEcCtD
Lubiprostone—Dizziness—Doxorubicin—lung cancer	9.28e-05	0.000362	CcSEcCtD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	9.22e-05	0.00123	CbGpPWpGaD
Lubiprostone—Vomiting—Doxorubicin—lung cancer	8.92e-05	0.000348	CcSEcCtD
Lubiprostone—Rash—Doxorubicin—lung cancer	8.85e-05	0.000345	CcSEcCtD
Lubiprostone—Dermatitis—Doxorubicin—lung cancer	8.84e-05	0.000345	CcSEcCtD
Lubiprostone—CBR1—Metabolism—PIK3CG—lung cancer	8.79e-05	0.00117	CbGpPWpGaD
Lubiprostone—Headache—Doxorubicin—lung cancer	8.79e-05	0.000343	CcSEcCtD
Lubiprostone—CBR1—Metabolism—POMC—lung cancer	8.37e-05	0.00111	CbGpPWpGaD
Lubiprostone—Nausea—Doxorubicin—lung cancer	8.33e-05	0.000325	CcSEcCtD
Lubiprostone—CBR1—Metabolism—CREBBP—lung cancer	8.15e-05	0.00108	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—PIK3CD—lung cancer	7.73e-05	0.00103	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—ALB—lung cancer	7.63e-05	0.00101	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—PIK3CB—lung cancer	6.73e-05	0.000895	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—PTGS2—lung cancer	6.67e-05	0.000887	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—PTEN—lung cancer	5.82e-05	0.000774	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—EP300—lung cancer	5.55e-05	0.000738	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—PIK3CA—lung cancer	4.11e-05	0.000546	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—AKT1—lung cancer	3.35e-05	0.000446	CbGpPWpGaD
